MktsMarkets

Kymera Therapeutics, Inc.
NASDAQ: KYMRKey statistics
KYMR News
Stories mentioning KYMR from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 34,365 | 2,871 | 2,764 | 11,476 | 22,100 | 7,394 | 3,741 | 25,650 |
| Cost of Goods Sold | 34,365 | 2,871 | 2,764 | 11,476 | 22,100 | 7,394 | 3,741 | 25,650 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 98,162 | 83,831 | 74,094 | 78,388 | 80,255 | 71,817 | 60,410 | 59,202 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 118,519 | 100,766 | 95,285 | 96,033 | 96,526 | 88,149 | 75,865 | 76,575 |
| Operating Income (Loss) | (84,154) | (97,895) | (92,521) | (84,557) | (74,426) | (80,755) | (72,124) | (50,925) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 14,920 | 10,914 | 10,346 | 7,943 | 8,845 | 10,003 | 9,637 | 8,863 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (69,234) | (86,981) | (82,175) | (76,614) | (65,581) | (70,752) | (62,487) | (42,062) |
| Earnings Per Share (Basic) | (0.71) | (1.03) | (0.94) | (0.95) | (0.82) | (0.94) | (0.82) | (0.58) |
| Earnings Per Share (Diluted) | (0.71) | (1.03) | (0.94) | (0.95) | (0.82) | (0.94) | (0.82) | (0.58) |
| Weighted Average Shares Outstanding (Basic) | 97,534 | 84,491 | 87,300 | 80,449 | 80,147 | 75,044 | 76,126 | 73,059 |
| Weighted Average Shares Outstanding (Diluted) | 97,534 | 84,491 | 87,300 | 80,449 | 80,147 | 75,044 | 76,126 | 73,059 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About KYMR
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a stock listed on the Nasdaq Stock Market under the ticker symbol KYMR. It last traded at $121.13 (Nov 18, 2026, 9:30 AM ET), down 0.3% on the day. That gives Kymera Therapeutics a market capitalisation of $9.0B.
Over the past 52 weeks KYMR has traded between $62.91 and $142.92.
Revenue for the quarter ended Mar 31, 2026 was $34.4M; a net loss of $69.2M. Revenue was up 55.5% from $22.1M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $34.4M | -$69.2M | -201.5% |
| Dec 31, 2025 | $2.9M | -$87.0M | -3029.6% |
| Sep 30, 2025 | $2.8M | -$82.2M | -2973.0% |
| Jun 30, 2025 | $11.5M | -$76.6M | -667.6% |
From Kymera Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…